257 related articles for article (PubMed ID: 29744794)
1. Evaluation of risk factors for vancomycin-induced nephrotoxicity.
Park SJ; Lim NR; Park HJ; Yang JW; Kim MJ; Kim K; In YW; Lee YM
Int J Clin Pharm; 2018 Oct; 40(5):1328-1334. PubMed ID: 29744794
[TBL] [Abstract][Full Text] [Related]
2. Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database.
Cano EL; Haque NZ; Welch VL; Cely CM; Peyrani P; Scerpella EG; Ford KD; Zervos MJ; Ramirez JA; Kett DH;
Clin Ther; 2012 Jan; 34(1):149-57. PubMed ID: 22284995
[TBL] [Abstract][Full Text] [Related]
3. Incidence and predictors of vancomycin-associated nephrotoxicity.
Moh'd H; Kheir F; Kong L; Du P; Farag H; Mohamad A; Zurlo JJ
South Med J; 2014 Jun; 107(6):383-8. PubMed ID: 24945176
[TBL] [Abstract][Full Text] [Related]
4. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial.
Bosso JA; Nappi J; Rudisill C; Wellein M; Bookstaver PB; Swindler J; Mauldin PD
Antimicrob Agents Chemother; 2011 Dec; 55(12):5475-9. PubMed ID: 21947388
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with development of nephrotoxicity in patients treated with vancomycin versus daptomycin for severe Gram-positive infections: A practice-based study.
Barberan J; Mensa J; Artero A; Epelde F; Rodriguez JC; Ruiz-Morales J; Calleja JL; Guerra JM; Martínez-Gil I; Giménez MJ; Granizo JJ; Aguilar L
Rev Esp Quimioter; 2019 Feb; 32(1):22-30. PubMed ID: 30630306
[TBL] [Abstract][Full Text] [Related]
6. The Relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran's population: a retrospective analysis.
Horey A; Mergenhagen KA; Mattappallil A
Ann Pharmacother; 2012 Nov; 46(11):1477-83. PubMed ID: 23073306
[TBL] [Abstract][Full Text] [Related]
7. The Whole Price of Vancomycin: Toxicities, Troughs, and Time.
Jeffres MN
Drugs; 2017 Jul; 77(11):1143-1154. PubMed ID: 28573434
[TBL] [Abstract][Full Text] [Related]
8. Assessment of initial serum vancomycin trough concentrations and their association with initial empirical weight-based vancomycin dosing and development of nephrotoxicity in children: a multicenter retrospective study.
Matson KL; Shaffer CL; Beck GL; Simonsen KA
Pharmacotherapy; 2015 Mar; 35(3):337-43. PubMed ID: 25756622
[TBL] [Abstract][Full Text] [Related]
9. Vancomycin-associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors.
Meaney CJ; Hynicka LM; Tsoukleris MG
Pharmacotherapy; 2014 Jul; 34(7):653-61. PubMed ID: 24700598
[TBL] [Abstract][Full Text] [Related]
10. Nephrotoxicity in patients with vancomycin trough concentrations of 15-20 μg/ml in a pediatric intensive care unit.
Cies JJ; Shankar V
Pharmacotherapy; 2013 Apr; 33(4):392-400. PubMed ID: 23471688
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Vancomycin on Gram-Positive Bacterial Infection in Elderly Critical Patients and Risk Factors Associated With Nephrotoxicity.
Huang M; Wu H; Zhou J; Xu M; Zhou S
Arch Iran Med; 2018 Aug; 21(8):349-355. PubMed ID: 30113856
[TBL] [Abstract][Full Text] [Related]
12. Do vancomycin serum levels predict failures of vancomycin therapy or nephrotoxicity in cancer patients?
Kralovicová K; Spanik S; Halko J; Netriova J; Studena-Mrazova M; Novotny J; Grausova S; Koren P; Krupova I; Demitrovicova A; Kukuckova E; Krcmery V
J Chemother; 1997 Dec; 9(6):420-6. PubMed ID: 9491842
[TBL] [Abstract][Full Text] [Related]
13. Impact of pharmacist intervention on preventing nephrotoxicity from vancomycin.
Masuda N; Maiguma T; Komoto A; Haruki Y; Sugiyama T; Kondo S; Teshima D
Int J Clin Pharmacol Ther; 2015 Apr; 53(4):284-91. PubMed ID: 25740266
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of body weight-based vancomycin therapy and the incidence of nephrotoxicity: a retrospective study in the northwest of China.
Dong MH; Wang JW; Wu Y; Chen BY; Yu M; Wen AD
Int J Infect Dis; 2015 Aug; 37():125-8. PubMed ID: 26159843
[TBL] [Abstract][Full Text] [Related]
15. Vancomycin-induced nephrotoxicity in non-intensive care unit pediatric patients.
Kwak S; Kim JY; Cho H
Sci Rep; 2021 Oct; 11(1):20681. PubMed ID: 34667202
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for vancomycin nephrotoxicity and time course of renal function during vancomycin treatment.
Hirai T; Hanada K; Kanno A; Akashi M; Itoh T
Eur J Clin Pharmacol; 2019 Jun; 75(6):859-866. PubMed ID: 30770940
[TBL] [Abstract][Full Text] [Related]
17. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.
Lodise TP; Patel N; Lomaestro BM; Rodvold KA; Drusano GL
Clin Infect Dis; 2009 Aug; 49(4):507-14. PubMed ID: 19586413
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections.
Hermsen ED; Hanson M; Sankaranarayanan J; Stoner JA; Florescu MC; Rupp ME
Expert Opin Drug Saf; 2010 Jan; 9(1):9-14. PubMed ID: 20021290
[TBL] [Abstract][Full Text] [Related]
19. Trough concentration over 12.1 mg/L is a major risk factor of vancomycin-related nephrotoxicity in patients with therapeutic drug monitoring.
Han HK; An H; Shin KH; Shin D; Lee SH; Kim JH; Cho SH; Kang HR; Jang IJ; Yu KS; Lim KS
Ther Drug Monit; 2014 Oct; 36(5):606-11. PubMed ID: 24577126
[TBL] [Abstract][Full Text] [Related]
20. Relationship Between Initial Vancomycin Trough Levels and Early-Onset Vancomycin-Associated Nephrotoxicity in Critically Ill Patients.
Chuma M; Makishima M; Imai T; Tochikura N; Suzuki S; Kuwana T; Sawada N; Komatsu T; Sakaue T; Kikuchi N; Yoshida Y; Kinoshita K
Ther Drug Monit; 2018 Feb; 40(1):109-114. PubMed ID: 29095798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
